Mereo BioPharma reported cash from operations of -$6.04M and free cash flow of -$6.04M for the quarter ended Jun 2026, up 21.0% year over year. This cash flow statement covers 16 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2021 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -12.08M | -1.75M | -6.53M | -9.11M | -8.95M | -12.26M | -15.00M | -17.91M | -12.89M | -14.62M | -7.02M | -17.77M | -6.72M | -7.00M | ||
| Share-based Compensation | 5.32M | 8.04M | 1.64M | 0.94M | 1.53M | 0.81M | 11.85M | 11.60M | 11.27M | 1.51M | 13.60M | 14.20M | 14.20M | 1.54M | 19.89M | 19.83M |
| Gains from Investment Securities | -0.54M | 0.10M | 0.20M | 0.45M | 0.07M | 0.06M | -0.16M | -0.42M | 0.10M | -0.20M | -0.29M | -0.02M | -0.01M | |||
| Cash from Operations | -9.25M | -7.75M | 2.66M | -6.79M | -7.99M | -7.90M | -7.52M | -9.42M | -8.33M | -7.65M | -7.31M | -7.68M | -4.31M | -6.04M | ||
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Amortizatization of Intangibles | 0.12M | 0.12M | 0.13M | 0.12M | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M | 0.14M | 0.13M | 0.13M | 0.13M | 0.13M | ||
| Change in Working Capital | ||||||||||||||||
| Change in Account Payables | 0.81M | -2.31M | -0.76M | 0.99M | 0.13M | 0.24M | -1.06M | 0.84M | 0.36M | -1.95M | -0.24M | 0.45M | 1.96M | -2.14M | ||
| Change in Accured Expenses | -3.10M | 4.25M | -0.15M | -1.71M | -2.94M | 3.25M | -0.79M | -0.71M | -1.39M | 1.93M | -0.67M | -2.26M | 0.23M | 0.58M | ||
| Other Working Capital Changes | -3.29M | 9.40M | -8.53M | 1.84M | -1.94M | 1.29M | -0.87M | -1.47M | 0.27M | -0.63M | -0.19M | -0.19M | -0.27M | -0.68M | ||
| Investing Activities | ||||||||||||||||
| Capital Expenditures | 0.02M | |||||||||||||||
| Cash from Investing Activities | -0.42M | -0.70M | 0.00M | -0.32M | 0.30M | -0.30M | ||||||||||
| Financing Activities | ||||||||||||||||
| Other financing activities | 0.49M | |||||||||||||||
| Change in Capital Stock | ||||||||||||||||
| Net Shares Issued and Repurchased | 4.84M | 4.87M | 2.41M | 2.50M | 2.33M | 2.40M | 6.46M | |||||||||
| Net Equity Issued and Repurchased | 11.61M | 0.04M | ||||||||||||||
| Misc. | ||||||||||||||||
| Cash from Financing Activities | 7.91M | 46.78M | -0.59M | -0.04M | 0.42M | -0.13M | 0.04M | |||||||||
| Exchange Rate Effect | 1.29M | 0.85M | -1.00M | 1.68M | -0.07M | -0.11M | 1.20M | -1.26M | 0.91M | 1.43M | -0.42M | -0.06M | -0.16M | -0.06M | ||
| Change in Cash | -9.67M | -7.69M | 11.70M | -5.11M | -8.69M | 38.88M | -8.11M | -9.46M | -8.23M | -7.79M | -7.01M | -7.64M | -4.61M | -6.04M | ||
| Free Cash Flow | -9.25M | -7.75M | 2.66M | -6.79M | -7.99M | -7.90M | -7.52M | -9.42M | -8.35M | -7.65M | -7.31M | -7.68M | -4.31M | -6.04M | ||
| Net Cash Flow | -9.67M | -7.75M | 10.56M | -6.79M | -8.69M | 38.88M | -8.11M | -9.46M | -8.23M | -7.79M | -7.01M | -7.64M | -4.61M | -6.04M |